Syntara Limited (ASX: SNT), a clinical-stage drug development company, is pleased to announce an update on its skin scarring programs, led by the Phase 1b study of SNT-9465, its second-generation topical pan-lysyl oxidase (pan-LOX) inhibitor.
- SNT-9465 Phase 1b study in hypertrophic sternotomy scars approaches completion of initial 20-participant cohort recruitment
- Study to be expanded to 30 participants, with blinded design maintained, to support a larger and robust dataset
- The Skin Hospital, Sydney, added as additional clinical site
- Top-line results expected in Q1 2027
- SNT-6302 exploratory keloid scar study: six participants complete 12-week treatment period; preliminary biological findings directionally consistent with observations from SOLARIA2
